NCT07211659View on ClinicalTrials.gov

Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Ovarian Cancer

Interventions

BIOLOGICAL

THEO-260

Oncolytic virus

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

Theolytics Limited

INDUSTRY